Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) and SPDR S&P Biotech ETF (NYSEArca: XBI) both decreased 5.8% while...